Skip NavigationSkip to Content
Return Return to Search Results

SARS-CoV-2 IgG Spike antibody levels and avidity in natural infection or following vaccination with mRNA-1273 or BNT162b2 vaccines

  1. Author:
    Hickey,Thomas
    Kemp,Troy
    Bullock,Jimmie
    Bouk,Aaron
    Metz,Jordan
    Neish,Abigail
    Cherry, James
    Lowy, Douglas R
    Pinto,Ligia

  2. Author Address

    Vaccine, Immunity and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Center for Cancer Research, National Cancer Institute, Frederick, MD, USA., Protein Expression Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA., Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.,
    1. Year: 2023
    2. Date: Jun 01
    3. Epub Date: 2023 06 01
  2. Journal: Human Vaccines & Immunotherapeutics
    1. Pages: 2215677
  4. Type of Article: Article
  5. Article Number: 2215677
  1. Abstract:

    Certain aspects of the immunogenicity and effectiveness of the messenger ribonucleic acid (mRNA) vaccines (mRNA-1273 and BNT162b2) developed in response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic are still uncharacterized. Serum or plasma samples from healthy donor recipients of either vaccine (BNT162b2 n = 53, mRNA-1273 n = 49; age 23-67), and individuals naturally infected with SARS-CoV-2 (n = 106; age 18-82) were collected 0-2 months post-infection or 1- and 4 months after second dose of vaccination. Anti-Spike antibody levels and avidity were measured via an enzyme-linked immunosorbent assay (ELISA). Overall, vaccination induced higher circulating anti-Spike protein immunoglobulin G (IgG) antibody levels and avidity compared to infection at similar time intervals. Both vaccines produced similar anti-Spike IgG concentrations at 1 month, while mRNA-1273 demonstrated significantly higher circulating antibody concentrations after 4 months. mRNA-1273 induced significantly higher avidity at month 1 compared to BNT162b2 across all age groups. However, the 23-34 age group was the only group to maintain statistical significance by 4 months. Male BNT162b2 recipients were approaching statistically significant lower anti-Spike IgG avidity compared to females by month 4. These findings demonstrate enhanced anti-Spike IgG levels and avidity following vaccination compared to natural infection. In addition, the mRNA-1273 vaccine induced higher antibody levels by 4 months compared to BNT162b2.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1080/21645515.2023.2215677
  3. PMID: 37264688

Library Notes

  1. Fiscal Year: FY2022-2023
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel